Addressing large-scale viral vector manufacturing using an optimized PEI-based transfection process
With the progress in developing new viral vector systems guided by safety, specificity and potency considerations, several gene and cell based therapies are now more than ever closer to being clinically approved and commercially available to treat genetic diseases. Viral vector delivery systems, of which mainly adeno-associated viruses (AAV) and lentiviruses are produced by transient transfection of mammalian producer HEK-293 cell lines. Virus vector production using the right transient transfection method is crucial to provide the flexibility and reproducibility that is needed to scale-up from initial process development to manufacturing of high-quality grade viral vectors.
Our solutions for virus production
PEIpro® is a DNA transfection reagent for production of viruses, recombinant proteins and antibodies either in adherent cells in presence of serum or in suspension HEK-293 cells grown in low serum or serum-free media.
PEIpro®-HQ is a highly qualified grade of PEIpro® reagent, especially developed for the production of clinical batches of recombinant proteins, antibodies or viral vectors. The PEIpro®-HQ grade is supplied with appropriate Quality Controls and documentation allowing its use as a qualified raw material in GMP processes for the manufacturing of clinical batches of therapeutic products.
FectoPRO® Transfection kit is specifically designed for enhanced Transient Gene Expression (TGE) in suspension CHO and HEK-293 cells in various serum-free media, using low DNA amount (< 1 µg/ml of cell culture).
The convention will take place in Norfolk, Virginia, United States:
Meet Valérie Kedinger to discuss how to improve your process of virus production. We will be happy to answer all your questions regarding transfection and to present relevant products adapted to bioproduction.
Valérie Kedinger, PhD
Clinical Key Account Manager